The prevalence and antibiotic susceptibility pattern of carbapenem-resistant Enterobacteriaceae in an Iranian burn center
DOI:
https://doi.org/10.61882/jcbior.4.3.237Keywords:
Antibiotic resistance, Burn wound, Nosocomial infectionAbstract
Carbapenems are a class of β-lactam antibiotics that are commonly used to treat multidrug-resistant (MDR) Gram-negative bacteria. However, the emergence of carbapenem-resistant strains and rapid spread across all continents become a major public health concern. In this regard, we aimed to investigate the prevalence and antibiotic resistance pattern of carbapenem-resistant Enterobacteriaceae (CRE) in an Iranian burn center. This retrospective cross-sectional study was performed during three years from March 2018 to March 2021 on burn victims who referred to a burn specialist hospital in the North of Iran. All bacterial isolates were differentiated and confirmed by standard microbiology methods. Disc diffusion method was applied to determine the antibiotic susceptibility pattern. CRE was defined as an isolate resistant to imipenem or/and meropenem. Totally, 33 out of 127 (26%) Enterobacteriaceae samples were resistance to carbapenem. Also, 66.7% of CRE were isolated from ICU and 33.3% from surgery ward. The majority of CRE (66.7%) was associated with surgical site infections (SSIs). The most prevalent CRE among the clinical samples was Klebsiella spp. (75.8%), followed by Escherichia coli (12.1%), Proteus spp. (9.1%), and Enterobacter spp. (3%), respectively. The antibiotic susceptibility pattern showed amikacin with 53.3% susceptibility as the most effective agents against CRE isolates. Despite the low level of CRE in our study, the high level of drug resistance among these isolates necessitating the use of unique infection control strategies and rigorous adherence to these guidelines.
References
1. Sartelli M, Bartoli S, Borghi F, Busani S, Carsetti A, Catena F, et al. Implementation Strategies for Preventing Healthcare-Associated Infections across the Surgical Pathway: An Italian Multisociety Document. Antibiotics (Basel). 2023;12(3). DOI: 10.3390/antibiotics12030521 PMID: 36978388
2. Liu JY, Dickter JK. Nosocomial Infections: A History of Hospital-Acquired Infections. Gastrointest Endosc Clin N Am. 2020;30(4):637-52. DOI: 10.1016/j.giec.2020.06.001 PMID: 32891222
3. Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pacific Journal of Tropical Biomedicine. 2017;7(5):478-82. DOI: 10.1016/j.apjtb.2017.01.019
4. Al-Tawfiq JA, Memish ZA. Mass gathering medicine: 2014 Hajj and Umra preparation as a leading example. Int J Infect Dis. 2014;27:26-31. DOI: 10.1016/j.ijid.2014.07.001 PMID: 25128639
5. Khan KS, Reed-Embleton H, Lewis J, Saldanha J, Mahmud S. Does nosocomial COVID-19 result in increased 30-day mortality? A multi-centre observational study to identify risk factors for worse outcomes in patients with COVID-19. J Hosp Infect. 2021;107:91-4. DOI: 10.1016/j.jhin.2020.09.017 PMID: 32950587
6. Wang L, Du KN, Zhao YL, Yu YJ, Sun L, Jiang HB. Risk Factors of Nosocomial Infection for Infants in Neonatal Intensive Care Units: A Systematic Review and Meta-Analysis. Med Sci Monit. 2019;25:8213-20. DOI: 10.12659/MSM.917185 PMID: 31675354
7. Girou E, Stephan F, Novara A, Safar M, Fagon JY. Risk factors and outcome of nosocomial infections: results of a matched case-control study of ICU patients. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1151-8. DOI: 10.1164/ajrccm.157.4.9701129 PMID: 9563733
8. Edwardson S, Cairns C. Nosocomial infections in the ICU. Anaesthesia & Intensive Care Med. 2019;20(1):14-8. DOI: 10.1016/j.mpaic.2018.11.004
9. Urrea M, Pons M, Serra M, Latorre C, Palomeque A. Prospective incidence study of nosocomial infections in a pediatric intensive care unit. Pediatr Infect Dis J. 2003;22(6):490-4. DOI: 10.1097/01.inf.0000069758.00079.d3 PMID: 12799503
10. Issler-Fisher AC, McKew G, Fisher OM, Harish V, Gottlieb T, Maitz PK. Risk factors for, and the effect of MRSA colonization on the clinical outcomes of severely burnt patients. Burns. 2015;41(6):1212-20. DOI: 10.1016/j.burns.2015.03.003 PMID: 26150350
11. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis. 2007;20(4):391-6. DOI: 10.1097/QCO.0b013e32818be6f7 PMID: 17609598
12. Sikora A, Zahra F. Nosocomial infections StatPearls [Internet]: StatPearls Publishing; 2022.
13. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016;35(10):1679-89. DOI: 10.1007/s10096-016-2710-0 PMID: 27401905
14. Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131(6):2715-38. DOI: 10.1111/jam.15130 PMID: 33971055
15. Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521-S8. DOI: 10.1093/cid/ciz824 PMID: 31724045
16. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403-34. DOI: 10.1128/CMR.19.2.403-434.2006 PMID: 16614255
17. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14. DOI: 10.1086/668770 PMID: 23221186
18. Aminu BM, Khadija ML. Antibacterial activity of local honey against Carbapenem Resistant enterobacteriaceae isolated from infected wounds. Bayero J Pure & Applied Sci. 2019;12(1):13-7. DOI: 10.4314/bajopas.v12i1.3S
19. Nasiri MJ, Mirsaeidi M, Mousavi SMJ, Arshadi M, Fardsanei F, Deihim B, et al. Prevalence and Mechanisms of Carbapenem Resistance in Klebsiella pneumoniae and Escherichia coli: A Systematic Review and Meta-Analysis of Cross-Sectional Studies from Iran. Microb Drug Resist. 2020;26(12):1491-502. DOI: 10.1089/mdr.2019.0440 PMID: 32348701
20. Correa AAF, Fortaleza C. Incidence and predictors of health care-associated infections among patients colonized with carbapenem-resistant Enterobacteriaceae. Am J Infect Control. 2019;47(2):213-6. DOI: 10.1016/j.ajic.2018.08.007 PMID: 30279017
21. Armin S, Fallah F, Karimi A, Karbasiyan F, Alebouyeh M, Rafiei Tabatabaei S, et al. Antibiotic Susceptibility Patterns for Carbapenem-Resistant Enterobacteriaceae. Int J Microbiol. 2023;2023:8920977. DOI: 10.1155/2023/8920977 PMID: 36860272
22. Davari N, Khashei R, Pourabbas B, Nikbin VS, Zand F. High frequency of carbapenem-resistant Enterobacteriaceae fecal carriage among ICU hospitalized patients from Southern Iran. Iranian J Basic Med Sci. 2022;25(12):1416.
23. Bahrami S, Shafiee F, Hakamifard A, Fazeli H, Soltani R. Antimicrobial susceptibility pattern of carbapenemase-producing Gram-negative nosocomial bacteria at Al Zahra hospital, Isfahan, Iran. Iran J Microbiol. 2021;13(1):50-7. DOI: 10.18502/ijm.v13i1.5492 PMID: 33889362
Downloads
Published
Issue
Section
License
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
